Correction

This article refers to:

Effectiveness and safety of apixaban, LMWH, and warfarin among high-risk subgroups of VTE patients with active cancer

Article title: Effectiveness and safety of apixaban, LMWH, and warfarin among high-risk subgroups of VTE patients with active cancer

Authors: Cohen, A. T., Keshishian, A., Lee, T., Rosenblatt, L., Hlavacek, P., Sah, J., & Luo, X.

Journal: Current Medical Research and Opinion

Bibliometrics: Volume 37, Number 09, pages 1467–1482

DOI: https://doi.org/10.1080/03007995.2021.1932448

When this article was first published online, the values of ‘Chemotherapy’ in Table 1 were incorrect. The values are now corrected as below and this article has been re-published online.

Table 1. Post-IPTW baseline characteristics among VTE patients with active cancer.

	Apixaban cohort	LMWH cohort	Warfarin cohort
	N = 3393	N = 6108	N = 4585
Age, mean (SD)	64.6 (12.6)	63.7 (13.2)	64.2 (12.9)
Modified CCI score, mean (SD)	2.0 (2.0)	2.0 (2.1)	1.9 (2.0)
Index VTE event type, n (%)
DVT only	1938 (57.1%)	3605 (59.0%)	2643 (57.6%)
PE with or without DVT	1455 (42.9%)	2503 (41.0%)	1942 (42.4%)
Cancer metastasis,^a n (%)
Yes	1727 (50.9%)	3172 (51.9%)	2344 (51.1%)
No metastasis	1666 (49.1%)	2936 (48.1%)	2241 (48.9%)
VTE risk level,^a n (%)
Very high risk	518 (15.3%)	921 (15.1%)	708 (15.4%)
High risk	1343 (39.6%)	2502 (41.0%)	1849 (40.3%)
Other	1532 (45.2%)	2685 (44.0%)	2028 (44.2%)
Cancer-related treatment,^a n (%)
Yes	2560 (75.4%)	4722 (77.3%)	3494 (76.2%)
Chemotherapy	2139 (63.0%)	3895 (63.8%)	2889 (63.0%)
Hormone therapy	364 (6.0%)	270 (5.9%)	201 (5.9%)
Immunotherapy	125 (2.0%)	94 (2.0%)	64 (1.9%)
Radiation	2197 (36.0%)	1638 (35.7%)	1180 (34.8%)
Cancer-related surgery	775 (12.7%)	611 (13.3%)	430 (12.7%)
No cancer treatment	833 (24.6%)	1386 (22.7%)	1091 (23.8%)
Chemotherapy,^a n (%)
Yes	2139 (63.0%)	3895 (63.8%)	2889 (63.0%)
No chemotherapy	1254 (37.0%)	2213 (36.2%)	1696 (37.0%)
GI cancer,^a n (%)
Yes	526 (15.5%)	994 (16.3%)	692 (15.1%)
No GI cancer	2867 (84.5%)	5114 (83.7%)	3893 (84.9%)

Abbreviations. CCI, Charlson comorbidity index; DVT, deep vein thrombosis; GI, gastrointestinal; IPTW, inverse probability treatment weighting; LMWH, Low-molecular-weight heparin; PE, Pulmonary embolism; SD, Standard deviation; VTE, Venous thromboembolism.

^aCancer-related variables were evaluated within 6 months prior until 30 days after the index date.